Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

CK2, a pleiotropic Ser/Thr kinase, is an important target for cancer therapy. We tested our novel tenfibgen-based nanocapsule for delivery of the inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) and an siRNA directed against both CK2α and α′ catalytic subunits to prostate cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Trembley, Janeen H., Unger, Gretchen M., Korman, Vicci L., Tobolt, Diane K., Kazimierczuk, Zygmunt, Pinna, Lorenzo A., Kren, Betsy T., Ahmed, Khalil
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3225714/
https://ncbi.nlm.nih.gov/pubmed/22050909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2011.10.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados